FFF Enterprises: BioSupply Trends Newsletter
Monday, September 18, 2017

Kedrion Biopharma and Kamada Receive FDA Approval for KEDRAB


In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly

The U.S. Food and Drug Administration has approved Kedrion Biopharma’s and Kamada’s KEDRAB (rabies immune globulin [human]) for passive, transient postexposure prophylaxis of rabies infection when given immediately after contact with a rabid or possibly rabid animal and administered concurrently with a full course of rabies vaccine. [ read more ]

Study Shows Increased Hospital Visits for Shingles Among Individuals Aged 20 to 59 Years

While emergency room visits for shingles has decreased for those vaccinated against either chicken pox (18 years to 19 years) or shingles (60 years and older), individuals aged 20 years to 59 years have experienced increased visits for the disease, according to a study. [ read more ]

Study Shows Fever During Pregnancy Increases Risk of Autism at Birth

Researchers at Columbia University in New York have found children born to mothers who experience fever, especially multiple fevers, during the second trimester of pregnancy are at increased risk for developing autism spectrum disorder.
[ read more ]

Industry News


From Octapharma USA

The U.S. Food and Drug Administration has approved new product strengths for Octapharma’s NUWIQ, offering added convenience by potentially reducing the number of vials needed for hemophilia A patients. [ read more ]

From Novartis

Novartis’ Kymriah (tisagenlecleucel) has been approved by the U.S. Food and Drug Administration to treat pediatric acute lymphoblastic leukemia.  [ read more ]

From AbbieVie Inc.

AbbieVie Inc.’s Mavyret (glecaprevir and pibrentasvir) has been approved by the U.S. Food and Drug Administration to treat adults with chronic hepatitis C virus genotypes 1-6 without cirrhosis or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. [ read more ]

IVIG & Albumin Supply Index


What's New at FFF


ROCURONIUM BROMIDE (injection) is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is supplied in 50 mg/5 mL and 100 mg/10 mL multiple-dose vials in packages of 10.

For more information about ROCURONIUM BROMIDE,
login to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective July 1, 2017, through Sept. 30, 2017.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
Carimune NF J1566 $65.88 $64.83
Flebogamma J1572 $55.86 $54.96
Gammagard S/D J1566 $65.88 $64.83
Gammaplex J1557 $93.38 $91.88
Octagam J1568 $68.25 $67.16
Privigen J1459 $77.21 $75.97
CUVITRU ** J3490/J3590/J7799 - -
Hizentra J1559 $98.29 $96.71
HyQvia J1575 $130.36 $128.27
Gammagard Liquid J1569 $80.39 $79.10
Gammaked J1561 $76.82 $75.59
Gamunex-C J1561 $76.82 $75.59

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.



FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2017 FFF Enterprises, Inc.
This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.